A regulatory chill is emerging as the FDA signals tighter controls on clinical trials that transfer Americans’ cells to China for genetic engineering before reinfusion. Provoked by biosecurity concerns and geopolitical tensions, especially the Trump-era hawkish stance, this move risks slowing collaborations and investments in Chinese-developed drugs poised for US markets. Industry experts warn that increased security scrutiny may reshape international biotech partnerships between these major drugmaking nations.